相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Response to: 'Beware of wolves in sheep's clothing: immune cell plasticity and instability in health and disease' by Alunno et al
Abdulla Watad et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Efficacy and Safety of Guselkumab, an Interleukin-23p 19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis
Iain B. McInnes et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Metaanalysis
Ahmed Mourad et al.
JOURNAL OF RHEUMATOLOGY (2020)
Interleukin-23 pathway at the enthesis: The emerging story of enthesitis in spondyloarthropathy
Charlie Bridgewood et al.
IMMUNOLOGICAL REVIEWS (2020)
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Philip J. Mease et al.
LANCET (2020)
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Atul Deodhar et al.
LANCET (2020)
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
GUSELKUMAB, AN IL-23 INHIBITOR THAT SPECIFICALLY BINDS TO THE IL23P19-SUBUNIT, FOR ACTIVE PSORIATIC ARTHRITIS: ONE YEAR RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PATIENTS WHO WERE BIOLOGIC-NAIVE OR TNF-A INHIBITOR-EXPERIENCED
C. T. Ritchlin et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study
Elizabeth G. Araujo et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Identification of myeloid cells in the human enthesis as the main source of local IL-23 production
Charlie Bridgewood et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Evidence that tissue resident human enthesis γδT-cells can produce IL-17A independently of IL-23R transcript expression
Richard James Cuthbert et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis
Dafna D. Gladman et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
Laura C. Coates et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Enthesitis: A hallmark of psoriatic arthritis
Gurjit S. Kaeley et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)
Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis
Ellen M. Gravallese et al.
NATURE REVIEWS RHEUMATOLOGY (2018)
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease et al.
ARTHRITIS CARE & RESEARCH (2017)
Clinical Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort: Incidence, Prevalence, Characteristics, and Outcome
Ari Polachek et al.
ARTHRITIS CARE & RESEARCH (2017)
Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis
Martin Bergman et al.
ARTHRITIS RESEARCH & THERAPY (2017)
Enthesitis New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment
Amy S. Kehl et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Interleukin-23-Dependent/T Cells Produce Interleukin-17 and Accumulate in the Enthesis, Aortic Valve, and Ciliary Body in Mice
Annika Reinhardt et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double- blind randomised placebo- controlled study (RAPID-PsA)
P. J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Is the Madrid Sonographic Enthesitis Index Useful for Differentiating Psoriatic Arthritis from Psoriasis Alone and Healthy Controls?
Lihi Eder et al.
JOURNAL OF RHEUMATOLOGY (2014)
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes et al.
LANCET (2013)
Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial
Arthur Kavanaugh et al.
ARTHRITIS AND RHEUMATISM (2012)
IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells
Jonathan P. Sherlock et al.
NATURE MEDICINE (2012)
Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment
L. C. Coates et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Psoriatic arthritis: Correlation between imaging and pathology
Ai Lyn Tan et al.
JOINT BONE SPINE (2010)
Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease
D. McGonagle
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2009)
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
Alice Gottlieb et al.
LANCET (2009)
Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis
Paul J. Healy et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Classification criteria for psoriatic arthritis - Development of new criteria from a large international study
William Taylor et al.
ARTHRITIS AND RHEUMATISM (2006)
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2005)
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)
CE Antoni et al.
ARTHRITIS AND RHEUMATISM (2005)
Etanercept treatment of psoriatic arthritis - Safety, efficacy, and effect on disease progression
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2004)
分享论文
